Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

NY-ESO-1 TCR-T cell therapy

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Gilead

Drug class:

PD1 inhibitor, TCR modulator, NY ESO 1 inhibitor

Related drugs:

GSK2241658A (0)

MultiTAA T cell therapy (0)

TCRT-ESO-A2 (0)

pembrolizumab (727)

nivolumab (607)

sintilimab (115)

toripalimab-tpzi (88)

camrelizumab (85)

tislelizumab-jsgr (84)

dostarlimab-gxly (43)

cemiplimab-rwlc (29)

zimberelimab (20)

pucotenlimab (12)

cadonilimab (10)

serplulimab (7)

retifanlimab-dlwr (6)

PF-06801591 (6)

JNJ-63723283 (5)

nivolumab/relatlimab-rmbw (4)

geptanolimab (3)

iparomlimab/tuvonralimab (3)

ivonescimab (3)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

enlonstobart (0)

prolgolimab (0)

prolgolimab/nurulimab (0)

nivolumab and hyaluronidase-nvhy (0)

PD-1-KO-T cell injection (0)

PF-07209960 (0)

Undisclosed PD-1 inhibitor (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

afamitresgene autoleucel (3)

FH-TCR-Tᴍsʟɴ (0)

HA-1 T TCR T Cell Immunotherapy (0)

MAGE A3 TCR (0)

NY-ESO-1 TCR (0)

T-Plex-200-A0201/204-A0201 (0)

T-cell receptor therapy (0)

TSC-200-A0201 (0)

TSC-204-A0201 (0)

TSC-204-C0702 (0)

mono TRuC-T CD70 cell therapy (0)

multiplexed MAGEA1/PRAME TCR-T cell therapy (0)

GSK2241658A (0)

MultiTAA T cell therapy (0)

TCRT-ESO-A2 (0)

›